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BACKGROUND: Hypertrophic cardiomyopathy (HCM) is caused by pathogenic 
variants in sarcomere protein genes that evoke hypercontractility, poor relaxation, 
and increased energy consumption by the heart and increased patient risks for 
arrhythmias and heart failure. Recent studies show that pathogenic missense 
variants in myosin, the molecular motor of the sarcomere, are clustered in 
residues that participate in dynamic conformational states of sarcomere proteins. 
We hypothesized that these conformations are essential to adapt contractile 
output for energy conservation and that pathophysiology of HCM results from 
destabilization of these conformations.
METHODS: We assayed myosin ATP binding to define the proportion of myosins 
in the super relaxed state (SRX) conformation or the disordered relaxed state 
(DRX) conformation in healthy rodent and human hearts, at baseline and in 
response to reduced hemodynamic demands of hibernation or pathogenic HCM 
variants. To determine the relationships between myosin conformations, sarcomere 
function, and cell biology, we assessed contractility, relaxation, and cardiomyocyte 
morphology and metabolism, with and without an allosteric modulator of myosin 
ATPase activity. We then tested whether the positions of myosin variants of 
unknown clinical significance that were identified in patients with HCM, predicted 
functional consequences and associations with heart failure and arrhythmias.
RESULTS: Myosins undergo physiological shifts between the SRX conformation 
that maximizes energy conservation and the DRX conformation that enables 
cross-bridge formation with greater ATP consumption. Systemic hemodynamic 
requirements, pharmacological modulators of myosin, and pathogenic myosin 
missense mutations influenced the proportions of these conformations. 
Hibernation increased the proportion of myosins in the SRX conformation, 
whereas pathogenic variants destabilized these and increased the proportion of 
myosins in the DRX conformation, which enhanced cardiomyocyte contractility, 
but impaired relaxation and evoked hypertrophic remodeling with increased 
energetic stress. Using structural locations to stratify variants of unknown clinical 
significance, we showed that the variants that destabilized myosin conformations 
were associated with higher rates of heart failure and arrhythmias in patients 
with HCM.
CONCLUSIONS: Myosin conformations establish work-energy equipoise that is 
essential for life-long cellular homeostasis and heart function. Destabilization of 
myosin energy-conserving states promotes contractile abnormalities, morphological 
and metabolic remodeling, and adverse clinical outcomes in patients with HCM. 
Therapeutic restabilization corrects cellular contractile and metabolic phenotypes 
and may limit these adverse clinical outcomes in patients with HCM.
© 2020 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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Muscle cells must balance work demands with energetic costs, processes that are particularly critical for cardiomyocytes that continuously 
function in heart muscle. Cardiac work must also ac-
commodate vast changes in systemic hemodynamic 
parameters that are high during intense physical exer-
cise but low during the deepest phases of sleep when 
energy can be conserved. Although overall cardiac per-
formance is modulated by multiple, integrated signals 
emanating from many organ systems, fundamentally 
these converge at the sarcomere, the essential unit of 
contraction in cardiomyocytes and other muscle cells. In 
the heart, sarcomere power is regulated by changes in 
beat rate, sarcomere length, denoted as length-depen-
dent activation,1,2 intracellular calcium flux,3 and phos-
phorylation of titin, troponin I, myosin-binding protein 
C, and myosin regulatory chain.4–9 When greater sarco-
mere power is needed, these processes augment the 
numbers of myosin molecules available for cross-bridge 
formation with the thin filament and increase ATP con-
sumption.
Myosin is the enzymatic molecular motor of the sar-
comere that hydrolyzes ATP to propel cyclical interac-
tions with thin filament actin. Within sarcomeres, only 
10% of myosin molecules are estimated to be involved 
in sarcomere force production,10 an observation that 
implies a mechanism(s) whereby unneeded myosins 
are prevented from forming inappropriate cross bridges 
causing unnecessary energy expenditure. Biochemical 
analyses11 and recent structural data12,13 imply that dy-
namic conformational changes between paired myo-
sin molecules provide a structural mechanism for this 
energy-conserving state. During relaxation, head do-
mains of paired myosin molecules appear to engage via 
an interacting-heads motif (IHM), and assume either a 
super relaxed state (SRX) conformation  in which both 
ATP-binding domains are sterically inhibited and unable 
to bind actin, or a disordered state (DRX) conformation 
in which only one myosin head is available to hydro-
lyze ATP and interact with actin.12 This model predicts 
that the proportion of myosins in these conformations 
would influence both contractility and energy usage 
and provide a mechanism to balance work and meta-
bolic costs that enables life-long cardiac function.
MYH7 and MYBPC3, which respectively encode the 
predominant adult cardiac myosin isoform and myo-
sin-binding protein C, harbor the majority of patho-
genic variants that cause hypertrophic cardiomyopathy 
(HCM),14 a primary myocardial disorder characterized 
by hyperdynamic contraction, poor relaxation, and 
increased energy consumption. Most HCM variants 
in MYBPC3 encode truncations that increase myosin 
contractility,15 concurrent with a shift in the proportion 
of myosins in DRX.15–17 By contrast, all HCM variants 
in MYH7 encode missense residues and the cellular ef-
fects of these subtle changes on myosin SRX and DRX 
conformations are largely unknown. Indeed, previous 
biophysical and biochemical analyses of isolated single 
myosin head fragments with HCM variants do not con-
sistently demonstrate gain of function,14,18–24 as might 
be predicted by a conformational shift toward DRX.
HCM is clinically diagnosed by imaging studies that 
demonstrate increased ventricular wall thickness, or 
hypertrophy, a morphological phenotype that is pre-
sumed to be caused by enlarged cardiomyocytes and 
increased amounts of myocardial fibrosis. HCM often 
causes arrhythmias, most often atrial fibrillation, and, in 
some patients, heart failure and premature death. Re-
cent analyses of >4500 patients with HCM showed that 
heart failure and arrhythmic risks were tiered accord-
ing to sarcomere protein genotype: highest in patients 
with pathogenic or likely pathogenic variants, interme-
diate among patients with variants of unknown clinical 
significance (VUS), and lowest in patients without sar-
comere variants.14 These epidemiological observations 
Clinical Perspective
What Is New?
• The proportion of myosin molecules in 2 confor-
mations (super relaxed state; SRX and disordered 
relaxed state; DRX) provide a fundamental mecha-
nism for enabling efficient myocardial performance 
and conservation of energy.
• Hypertrophic cardiomyopathy (HCM) mutations 
that disrupt the physiological balance myosins in 
the SRX and DRX conformations alter cardiomyo-
cyte contraction, relaxation, and metabolism, and 
convey increased risks for heart failure and atrial 
fibrillation.
• A small molecule can restore the physiological bal-
ance of myosins in the SRX and DRX conformations 
and disordered relaxed state of myosin molecule 
and improve functional, energetic, and cellular 
abnormalities that occur in patients with HCM.
What Are the Clinical Implications?
• Normal relaxation by cardiomyocytes is profoundly 
important for life-long heart function, and the dis-
ruption of this property increases risks for adverse 
clinical outcomes.
• The identity of amino acids that participate in con-
formational interactions during cardiac relaxation 
provides a new strategy to better classify HCM 
variants, including those of unknown significance, 
to define patients with HCM and high risks for 
adverse outcomes.
• A small molecule that normalizes the fundamental 
abnormalities caused by HCM mutations provides 
a therapeutic opportunity to limit the development 
of hypertrophy, diastolic dysfunction, atrial fibrilla-
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infer that clinical outcomes may reflect different bio-
physical properties of HCM variants and their effects on 
the cardiomyocyte biology.
Here we probed the unknown physiological effects 
of myosin DRX and SRX conformations on cardiomyo-
cyte biology. We tested whether the evolutionarily 
conserved IHM25 provided an adaptable mechanism 
to promote myosin in the SRX or DRX conformations, 
by studying hibernating mammalian hearts in different 
stages of torpor or arousal. We contrasted these analy-
ses with studies of human cardiomyocytes with normal 
myosin sequences or with pathogenic variants that 
disrupted IHM residues. We determined the effects on 
myosin SRX and DRX conformations, and cardiomyo-
cyte contractility, sarcomere content, cell size, and cell 
metabolism. Using a myosin allosteric modulator, MYK-
461, we assayed the direct cellular effects of altering 
the balance of myosin conformational states. Lastly, we 
extended experimentation to address whether changes 
in biophysical and cellular properties associated with 
myosin VUS correlated with clinical adverse outcomes 
in patients with HCM. Together our data provide deep-
er insights into the importance of regulating myosin 
conformations in health and disease.
METHODS
The data that support the findings of this study are avail-
able within the article and the online-only Data Supplement. 
Requests for reagents and anonymized human data from 
qualified researchers trained in human subject confidentiality 
protocols may be sent to the corresponding authors.
We studied HCM mutations in myosin using mouse mod-
els, isogenic human cardiomyocytes, and heart tissues with 
different background genotypes. Mouse models express 
mutations in Myh6, whereas isogenic cardiomyocytes derived 
from induced pluripotent stem cells (iPSC-CMs) express muta-
tions in MYH7. Comparative assays of mouse and human 
cardiomyocytes were used to determine if functional differ-
ences observed in mutations were influenced by these spe-
cies-specific myosin isoforms. Human cardiomyocytes were 
derived from a parental induced pluripotent stem cell line 
that carried a green-fluorescent protein tag on one titin allele 
(denoted  GFP-tagged iPSC-CMs).26,27 HCM variants were 
engineered into the endogenous MYH7 gene in this line to 
compare mutational effects within an isogenic background. 
Mutant iPSC-CMs were used to study live cell contractility, 
energetics, and metabolism. Parallel analyses in isolated car-
diomyocytes from mouse HCM models and human HCM 
heart tissues were used to validate that iPSC-CM findings also 
occurred in vivo.
Rodent Studies
All animal experiments were performed in accordance with 
protocols that were reviewed and approved by institu-
tional boards in accordance with the Animal Care and Use 
Committee of the University of Western Ontario and Harvard 
Medical School. Ventricular heart tissues were snap frozen in 
liquid N2 immediately on excision from 13-lined ground squirrel 
(Ictidomys tridecemlineatus) during torpor, interbout euther-
mia, and arousal, as previously described.28 Cardiomyocytes 
and heart tissues were isolated from mice carrying human 
HCM mutations in the endogenous Myh6 gene,29,30 as pre-
viously described.11,15 Contraction and relaxation measure-
ments of isolated cardiomyocytes from 3 mice with identical 
genotype were performed as described previously.15
Human Studies
Human subjects participating in the Sarcomeric Human 
Cardiomyopathy Registry (SHaRe) were recruited after obtain-
ing written signed consent using protocols that were reviewed 
and approved by each institution of the participating SHaRe 
investigators, as previously described.14 The races and ethnici-
ties of SHaRe participants studied here (Table I in the online-
only Data Supplement) and information on left ventricular 
(LV) myocardial tissue samples (Table II in the online-only Data 
Supplement) are provided in the Extended Methods in the 
online-only Data Supplement.
All participants clinically diagnosed with HCM based on the 
finding of isolated and unexplained LV hypertrophy (maximal 
LV wall thickness ≥ 13 mm or Z-score for pediatric patients). 
Additional inclusion criteria required ≥1 clinic visit at a SHaRe 
site since 1960, ≥1 echocardiographic assessments of LV wall 
thickness, and available genetic test data on 8 sarcomere 
HCM genes: myosin-binding protein C (MYBPC3), β-myosin 
heavy chain (MYH7), cardiac troponin T (TNNT2), cardiac tro-
ponin I (TNNI3), α-tropomyosin (TPM1), myosin essential and 
regulatory light chains (MYL3, MYL2, respectively), and actin 
(ACTC). Sarcomere variants in these genes were reviewed by 
a subgroup of SHaRe investigators to standardize classifica-
tion,14 and patients were designated as SARC+ (≥1 patho-
genic or likely pathogenic variant in sarcomere genes), SARC 
VUS (in one of the sarcomere genes listed above), or SARC– 
(no pathogenic or likely variant in sarcomere genes). Patients 
with pathogenic or likely pathogenic variants in other genes 
implicated in LV hypertrophy were excluded.
Among 3695 patients meeting these criteria we selected 
all patients (n=2281) assigned as SARC+ or SARC VUS on 
the basis of MYH7, MYL2, or MYL3 genotypes, because 
these genes participate in the IHM.12 SARC VUS geno-
types (n=133) were reclassified on the basis of whether 
the variant altered an amino acid residue involved in the 
IHM (VUS IHM+) or not (VUS IHM–) using the previously 
described quasi-atomic IHM model (Research Collaboratory 
for Structural Bioinformatics, Protein Data Bank entry 5TBY 
and supplementary file 2 in reference 12).
We compared the incidence of adverse outcomes by using 
Kaplan-Meier analyses based on genotypes. Time to first 
occurrence of atrial fibrillation, a composite score of heart 
failure–related outcomes (time to first occurrence of cardiac 
transplantation, LV assist device implantation, LV ejection 
fraction <35%, or New York Heart Association class III/IV 
symptoms), and an overall composite including these metrics, 
and all-cause death, as well, were analyzed. These adverse 
events were analyzed from birth to assess the lifetime cumu-
lative incidence of clinical outcomes. Patients who did not 
have the outcome under analysis were censored at the time 
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data (occurrence or timing of an outcome) were excluded 
from analysis of that outcome.
LV heart samples were obtained from a subset of SHaRe 
participants undergoing procedures for clinical indications at 
Brigham and Women’s Hospital and the University of Michigan 
Medical Center. Tissues were snap frozen in liquid N2 immedi-
ately on excision and used in studies detailed below.
Derivation of Human iPSC-CMs With 
HCM Variants
Heterozygous HCM variants were introduced  into a MYH7 
allele in human isogenic iPSCs carrying GFP-tagged titin 
and differentiated into cardiomyocytes (iPSC-CMs) as 
described.26,27,31 iPSC-CMs with heterozygous HCM mis-
sense variants were studied on day 30 after differentiation, 
at which time myosin isoform expression was assessed (Table 
III in the online-only Data Supplement).
Mant-ATP Assays and Analyses
Mant-ATP assays were performed on 3 samples from mice 
or human LV and iPSC-CMs (day 30 differentiation) by 
using a published protocol.15 Monolayers of iPSC-CMs were 
scraped from 6 culture wells or isolated tissues were pinned 
onto the experimental flow chamber and incubated for 30 
minutes (room temperature) in permeabilization buffer. 
Chambers were then flushed with glycerin solution to allow 
storage (–20°C for 2 days) or immediate use. Three regions 
of the chamber were sampled for fluorescence decay analy-
ses as described.15,17
Morphological and Functional Analyses 
of Day 30 iPSC-CMs
Contractile measures of iPSC-CMs were performed on 3 indi-
vidual differentiations by using SarcTrack as described.26,27
Cell sizes were assessed after incubation with media 
containing 5 µg/mL wheat germ agglutinin, Alexa Fluor 
568 (ThermoFisher Scientific) for 10 minutes at 37°C. After 
washing, samples were imaged (Nikon Ti Eclipse epifluo-
rescence microscope) and ≥10 images acquired from 10 
regions for analyses (MATLAB program; The MathWorks) 
that quantified pixel intensity units between fluorescent 
cells and the dark background.
Mitochondrial content was assessed in detached iPSC-
CMs, incubated with 250 nmol/L Mitotracker Deep Red 
(ThermoFisher Scientific; 30 minutes, 37°C, 5% CO2). After 
washing, mitochondria were quantified by using BD FACS 
Canto II (Becton Dickinson) to assess ≥10 000 events per 
sample, and data were analyzed using Becton Dickinson 
FACS Diva. Readings for mean fluorescence intensity were 
recorded in arbitrary units.
Sarcomere content was assessed in single GFP-tagged 
iPSC-CMs plated on fibronectin-coated rectangular micro-
patterned substrate and polyacrylamide gels, and processed 
by a custom routine in ImageJ (National Institutes of Health) 
and MATLAB (Mathworks), as described previously.32,33 The 
spectra of 2-dimenstional Fourier transformed images were 
converted to a one-dimensional representation, normal-
ized and fitted to a function composed with an aperiodic 
component (to account for irregular cellular structures) and 
a periodic component representing regularly spaced sarco-
meres. The normalized area under the first nonzero peak of 
the periodic component was taken as a measure of the regu-
larity of the sarcomere structure.
Extracellular Flux and Metabolic Analyses 
of Day 30 iPSC-CMs
Extracellular flux analyses were performed on iPSC-CMs 
(8×104 cells) seeded on Geltrex-coated XF96 plates, with or 
without preincubation (24 hours) with MYK-461 (0.5 μmol/L, 
1 μmol/L, or vehicle) or 2-deoxy-d-glucose (5 mmol/L or vehi-
cle). Cellular oxygen consumption rate (OCR) and extracellular 
acidification rate were measured using a Cell Mito Stress Kit 
and a Seahorse XF96 Analyzer (Agilent Technologies) accord-
ing to the manufacturer’s instructions.
Statistical Analyses
Single comparisons were analyzed by using the Student t test, 
with significance defined as P<0.05. Multiple comparisons 
between genotypes were analyzed using 1-way ANOVA with 
post hoc Bonferroni corrections for multiple comparisons, with 
significance defined as P<0.05. Where multiple comparisons 
also used MYK-461 treatment, we applied 2-way ANOVA with 
post hoc Bonferroni corrections for multiple comparisons and 
assigned significance for P<0.05. SHaRe data were analyzed as 
previously described,14 using Kaplan-Meier analyses to assess 
differences by genotype with Cox proportional hazard model-
ing that controlled for age at diagnosis and sex.
Additional details are provided in the online-only Data 
Supplement.
RESULTS
Myosin heads that are in the SRX conformation cycle 
ATP slowly, whereas free myosin heads in the DRX con-
formation have 5-fold11 faster ATP turnover (Figure 1A). 
With the use of a fluorescent ATP analogue, Mant-
ATP, chased with nonfluorescent ATP (Figure  1B), the 
abundance of myosins in SRX and DRX conformations 
(Figure 1C) can be deconvoluted from the double-expo-
nential fluorescent decay pattern.11 Fast decay reflects 
myosins in the DRX conformation; slow decay reflects 
myosins in the SRX conformation.
Using this assay, we previously defined the propor-
tion of myosins in DRX (40%) and SRX (60%) confor-
mations in healthy mouse hearts,15 which agrees with 
a predicted SRX/DRX ratio of 1.5 in relaxed muscle.12 
To determine if the overall hemodynamic requirements 
and metabolic state of cardiac physiology correlated 
with shifts in SRX/DRX ratios, we studied the 13-lined 
ground squirrel (I tridecemlineatus), a mammalian hi-
bernator that spends winter in extended bouts of torpor 
with low core body temperature (5°C), markedly slow 
heart, respiratory, and metabolic rates (3% basal lev-
els), punctuated by spontaneous arousals to periods of 
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accurately predict these states and range from ≈340 
bpm during arousal, 311 bpm for interbout euthermia, 
to ≈6 bpm for torpor. Using this model to reflect the ex-
tremes in systemic physiological activity, we conducted 
Mant-ATP assays of hearts obtained during each state 
(Figure 1D through 1F) and found comparable propor-
tions of myosins in DRX (35%) and SRX (65%) con-
formations  during summertime arousal and interbout 
euthermia. By contrast, hearts obtained during torpor 
had increased proportions of the SRX (75%) conforma-
tion, suggesting that shifts in the balance of DRX and 
SRX  conformations provided ATP conservation during 
low needs for cardiac output and limited supplies of 
energy substrates. Because the IHM is conserved across 
vertebrate and invertebrate evolution,25 we suggest that 
this mechanism broadly contributes to the efficiency of 
mammalian muscles.35 These observations also imply 
deleterious effects from chronic distortion of physiolog-
ical proportions of DRX and SRX conformations.
HCM Myosin Missense Variants 
Destabilize the IHM
With evidence that energetic states were associated 
with proportions of myosins in DRX and SRX confor-
mations, we considered whether cardiac pathologies 
Figure 1. Mant-ATP assays assess physiological and pathological changes in cardiac myosin conformations.
A, Depiction of the predicted myosin SRX and DRX conformations, indicating the dynamic effects of the interacting heads motif, in torpor (Left), normal cardiac 
function, and in hypertrophic cardiomyopathy (Right). B, Schematics depicting Mant-ATP (M-ATP) infused into a flow chamber containing permeabilized cardiac 
tissue. A subsequent chase of dark ATP results in fast and slow fluorescence decay (detected at 448 nm using a 40× objective) from DRX and SRX conformations 
of myosins, respectively. C, Representative Mant-ATP fluorescent chase experiment in wild-type tissues, described by a double-exponential decay. D, Mant-ATP 
assays of myocardium from ground squirrel hearts, obtained during summer arousal, interbout euthermia (IBE), and torpor. E and F, Proportions of myosin heads 
in the DRX conformation (E) with higher rates of ATP cycling and in SRX conformation (F) with slower ATP cycling. Data were obtained from studies of 3 hearts in 
each physiological state, with 3 to 4 samples studied per heart and are plotted as mean±SEM, with significance tested in comparison with summer (arousal), by 
1-way ANOVA with Bonferroni correction with a significance cutoff at P<0.05. A.U. indicates arbitrary units; DRX, disordered relaxed state conformation of myosin 
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perturbed these ratios. We previously showed that 
human HCM pathogenic variants in MYH7, which en-
codes the cardiac β-myosin heavy chain, are clustered 
in residues that participate in IHM interactions,12 an ob-
servation that implied that missense residues might de-
stabilize the IHM and thereby alter the balance of DRX 
and SRX conformations. Residues 403 and 606 reside 
within the S1 myosin head (Figure  2A) and are posi-
tioned along the actin interface, whereas residue 719 
resides in the myosin converter domain. Each of these 
residues is predicted to participate in stabilizing IHM 
conformations. Residue 719 is also predicted to anchor 
one myosin head along the partnered myosin’s tail, an 
interaction that promotes the SRX conformation. HCM 
variants R403Q and R719Q also cause a –2 change in 
electrical charge,12 which could destabilize these IHM 
interactions (Figure  2B and 2C). To test these predic-
tions, we initially studied LV myocardium from mice 
carrying each of these heterozygous variants (R403Q, 
R719Q, and V606M)30 in Myh6 that encodes the mouse 
cardiac isoform, α-myosin heavy chain.
We performed Mant-ATP assays on cardiac LV tissue 
from young Myh6R403Q/+, Myh6V606M/+, and Myh6R719W/+ 
mice before morphological changes that indicate hy-
pertrophic remodeling. Each mutant heart showed a 
significantly more rapid Mant-ATP fluorescent decay 
in comparison with wild type (WT), corresponding 
to increased proportions of myosins in DRX and de-
creased in SRX conformations (Figure 2D and 2E and 
Figure I in the online-only Data Supplement). Applica-
tion of MYK-461 (see Methods), an allosteric modu-
lator of myosin ATPase activity, normalized the SRX/
DRX imbalance in Myh6V606M/+ hearts, and excessively 
increased SRX in comparison with DRX conformations 
in Myh6R403Q/+ and Myh6R719W/+ tissues.
Adult human ventricles express primarily β-myosin 
heavy chain (encoded by MYH7), with ≈93% amino 
acid sequence identity to α-myosin heavy chain, but 
with 2-fold slower actin sliding velocities and lower 
ATPase activity.36 To assess HCM variants in the context 
of β-myosin, we engineered heterozygous HCM vari-
ants into a MYH7 allele in human iPSCs that harbor a 
green fluorescent protein (GFP) tag on titin, so as to al-
low direct assessment of sarcomere performance.26,27,31 
Cardiomyocytes derived from iPSC-CMs with hetero-
zygous HCM missense variants were studied at day 
30 after differentiation, at which time RNA sequenc-
ing demonstrated 20-fold greater expression of MYH7 
than MYH6 (Table III in the online-only Data Supple-
ment) indicative of cardiomyocyte maturation. Analyses 
of DRX and SRX conformations in iPSC-CMs with nor-
mal MYH7 sequences had proportions of DRX and SRX 
conformations similar to those observed in WT mouse 
LV that express Myh6. By contrast, isogenic iPSC-CMs 
with heterozygous HCM missense variants in MYH7 
(Figure 2F and 2G), like variants in MYH6, significantly 
increased the proportion of myosins in the DRX con-
formation  in comparison with the  SRX  conformation 
in comparison with WT cardiomyocytes. Application of 
MYK-461 to mutant iPSC-CMs consistently normalized 
SRX/DRX conformations to levels observed in WT iPSC-
CMs.
Myosin Missense Variants in iPSC-CMs 
Evoke HCM Pathophysiology
Isolated mouse cardiomyocytes have highly ordered 
sarcomeres that propel uniform cellular contraction 
and relaxation (Figure  3A through 3F) unlike iPSC-
CMs. However, iPSC-CMs containing GFP-tagged titin 
enabled high-fidelity dynamic tracking of hundreds of 
individual sarcomeres31 for direct functional analyses 
(Figure 3G through 3L). Comparisons of isolated paced 
cardiomyocytes from WT and HCM mice (Figure  3C) 
and iPSC-CMs (Figure 3I) showed that each HCM vari-
ant caused hypercontractility. In addition, each variant 
also caused concurrent prolongation in the duration of 
relaxation in comparison with WT cardiomyocytes (Fig-
ure  3D and 3J). Because these changes in functional 
properties correlated with shifts in the proportions of 
myosins in DRX and SRX conformations, we deduced 
that increased contractility likely resulted from increased 
numbers of myosin in the DRX conformation, whereas 
delayed relaxation was attributable to decreased num-
bers of myosin in the  SRX  conformation. Consistent 
with this conclusion, application of MYK-461 to mouse 
cardiomyocytes and iPSC-CMs caused a dose-depen-
dent decrease in the numbers of myosin in DRX and 
in hypercontractility (Figure 3E and 3K). The prolonged 
relaxation was normalized to WT rates (Figure 3F and 
3L). These data indicate that the overall cardiac effects 
of MYK-461 may relate to the degree of shifting myo-
sin conformations, as has been suggested from in vitro 
analyses.37
IHM Destabilization Increases Cell Size 
and Sarcomere Content and Alters 
Cellular Metabolism
On the basis of the demonstration that pathogenic 
MYH7 missense variants, which destabilized the IHM, 
caused functional phenotypes (hypercontractility and 
poor relaxation), we considered whether or not IHM 
destabilization also affected cellular morphology and 
energetics. Hypertrophy, a prominent clinical compo-
nent of HCM, was assessed by comparing cell sizes of 
isogenic WT and mutant iPSC-CMs (Figure 4A and 4B). 
The mean area of unconstrained mutant cells was sig-
nificantly larger than WT cells (MYH7R403Q/+, P<0.001; 
MYH7 V606M/+, P<0.0001; MYH7R719W/+, P<0.001). In 
comparison with untreated mutant iPSC-CMs, expo-




 http://ahajournals.org by on A
pril 6, 2020
Toepfer et al Pathophysiologic Mechanisms of HCM Variants














Figure 2. Destabilization of the interacting heads motif (IHM) by pathogenic HCM variants alters the proportion of myosins in the SRX and DRX 
conformations in mouse myocardium and human iPSC-CMs.
A, Depiction of the functional domains of myosin, subunit 1 (S1), subunit 2 (S2), and light meromyosin (LMM), and the location of human MYH7 variants 
in patients with HCM: pathogenic variants (red), variants of unknown significance (VUS) that alter IHM residues (VUS IHM+, orange), and variants that alter 
residues outside the IHM (VUS IHM–, blue). B, The Protein Data Bank 5TBY model showing relaxed paired myosin heads, one with the ATP binding site blocked 
(olive) or accessible (green). The associated essential light chains (brown and purple), and regulatory light chains (dark blue and blue) are shown. Residues 
involved in the myosin IHM are depicted as a ribbon, with the location of 3 HCM pathogenic missense variants MYH7R403Q/+ (orange), MYH7V606M/+ (magenta), 
and MYH7R719W/+ (green). C, The same model shown in B and depicting the 3 HCM pathogenic missense variants (red), 2 VUS IHM+ (orange), and one VUS 
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significantly reduced cell areas (Figure 4B). We assessed 
sarcomere content by fluorescence-activated cell sort-
ing analysis of GFP-tagged titin iPSCs before differen-
tiation (Figure II in the online-only Data Supplement) 
and in mature iPSC-CMs by Fast Fourier Transform 
analyses (Figure 4C). In comparison with WT iPSC-CMs, 
sarcomere content was increased in MYH7R403Q/+and 
MYH7R719W/+ iPSC-CMs and not in MYH7V606M/+ (Fig-
ure 4C).
Given increased size and sarcomere content and the 
increased proportions of mutant myosins in DRX that 
would propel increased contractility and 5-fold greater 
ATP consumption,11 we assessed cellular energetics. Mi-
tochondrial content was increased in mutant lines (Fig-
ure 4D). Assays of cellular OCRs showed that basal rates 
of OCR were increased in mutant compared with WT iP-
SC-CMs, and mutant iPSC-CMs had greater capacity for 
maximal cellular respiration than that achieved by WT 
cells (Figure 4E). Because the addition of the glucose an-
alogue, 2-deoxy-d-glucose, markedly decreased oxygen 
consumption rates in mutant in comparison with WT iP-
SC-CMs (Figure 4F), we deduced that mutant cells used 
glycolysis to supplement energy requirements. Acute 
treatment of iPSC-CMs with MYK-461 (Figure 4G) re-
stored normal OCR (versus WT, P=not significant). We 
concluded from these data that increased cellular ener-
gy demands were driven by IHM destabilization, which 
increased myosin proportions in DRX. Pharmacological 
rebalancing of DRX:SRX proportions removed the in-
creased energetic burden in cardiomyocytes.
Figure 3. Pathogenic hypertrophic cardiomyopathy myosin variants in mouse cardiomyocytes and iPSC-CMs exhibit hypercontractility and abnormal 
relaxation that is normalized by interacting heads motif restabilization with MYK-461.
A, Mouse cardiomyocytes (×40 image) shows precise striations attributable to a well-organized sarcomere. B, Typical contractile waveform obtained by tracking 
strings of mouse cardiomyocyte sarcomeres during 1 Hz pacing. C and D, Sarcomere shortening (C) and relaxation durations (D) in WT, Myh6R403Q/+, Myh6V606M/+, 
and Myh6R719W/+ mouse cardiomyocytes taken from 3 hearts per genotype. E and F, Dose-dependent effects of acute MYK-461 application on sarcomere contractil-
ity (E, percent shortening) and relaxation (F) in paced mouse WT, Myh6R403Q/+, Myh6V606M/+, and Myh6R719W/+ cardiomyocytes from 3 hearts per genotype. G, Image 
of titin-green fluorescent protein–tagged iPSC-CM imaged at 100×, showing z-discs labeled by green fluorescence. H, Contractile waveform of a single sarcomere 
defined by a z-disc pair during 1 Hz pacing. I and J, Sarcomere shortening (I) and relaxation durations (J) in paced isogenic WT, MYH7R403Q/+, MYH7V606M/+, and 
MYH7R719W/+ iPSC-CMs from 3 separate differentiations. K and L, Dose-dependent effect of acute MYK-461 application on sarcomere contractility (K) and relax-
ation durations (L) in paced isogenic WT, MYH7R403Q/+, MYH7V606M/+, and MYH7R719W/+ iPSC-CMs from 3 separate differentiations. Significant differences to WT 
were assessed by 2-way ANOVA with post hoc Bonferroni correction from multiple comparisons, significances of P<0.05 indicated by *. All data are displayed as 
mean±SEM. iPSC-CMs indicates isogenic cardiomyocytes derived from induced pluripotent stem cells; and WT, wild type cardiomyocytes.
Figure 2 Continued. D and E, Proportion of myosin heads in DRX and SRX conformations in WT, Myh6403/+, Myh6606/+, and Myh6719/+ in 8-week-old mouse LV 
myocardium, in the presence or absence of 0.3 μmol/L MYK-461 as indicated. (See also Figure I in the online-only Data Supplement). F and G, Proportion of myo-
sin heads in DRX and SRX conformations in WT, MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs in the presence or absence of 0.3 μmol/L MYK-461 as indicated. 
Data are from 3 independent heart tissues or differentiations of iPSC-CMs and are presented as means±SEM. Significance was tested by 1-way ANOVA and post 
hoc Bonferroni corrections for significances are denoted in the figure. Significances are reported in relation to WT values; bars encompassing significance values 
indicate that statistical significance is shared among these samples. DRX indicates disordered relaxed state conformation of myosin molecule; HCM, hypertrophic 
cardiomyopathy; iPSC-CMs, isogenic cardiomyocytes derived from induced pluripotent stem cells; NS, not significant; SRX, super relaxed state conformation of 
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Figure 4. MYH7 variants affect sarcomere content and cell size in iPSC-CMs.
A, Representative images obtained of WT and MYH7R403Q/+ iPSC-CMs used for calculating cellular spread area. B, Mean cell spreading areas observed with un-
constrained seeding onto glass slides of iPSC-CMs: WT (n=632), MYH7R403Q/+ (n=530), MYH7V606M/+ (n=479), and MYH7R719W/+ (n=655), iPSC-CMs (MYH7R403Q/+, 
n=665; MYH7V606M/+, n=531; MYH7R719W/+, n=653) were treated with 1 μmol/L MYK-461 for 24 hours, and the spreading areas were measured. Data pre-
sented are from 3 separate differentiations with the mean±SEM displayed for each measure. Significances are measured by 2-way ANOVA with multiple com-
parison corrections and a significance cutoff of P<0.05. The P values above bars compare areas of untreated mutant and WT iPSC-CMs. The P values without 
bars reflect comparisons of MYK-461 treated to untreated cells with the same genotype. C, Sarcomere content assessed by Fast Fourier Transform analyses 
of WT, MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs. Data presented are from 3 separate differentiations with mean±SEM displayed for each measure. 
Statistical significance was assessed by 1-way ANOVA with post hoc Bonferroni correction for multiple comparisons with a significance cutoff of P<0.05. D, 
Mitochondrial abundance assessed by Mitotracker intensity between WT, MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs. E, Extracellular-flux analyses during 
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We considered whether ATP levels were altered in 
MYH7 variants or were stable because of supplemental 
sources that accommodated increased energy require-
ments.38 Using mass spectrometry, we compared WT and 
mutant iPSC-CMs to assess phosphocreatine and ATP 
levels and phosphocreatine/ATP and NAD/NADH ratios. 
In comparison with WT cells, mutant iPSCs had reduced 
phosphocreatine levels (P=0.05, Figure  5A) but stable 
ATP levels (Figure 5B), likely because of significantly re-
duced phosphocreatine/ATP levels (P=0.05, Figure 5C). 
In addition, mutant iPSC-CMs had increased NAD/NADH 
ratios (P<0.01, Figure 5D). Because our analyses showed 
that 2-deoxy-d-glucose–treated iPSC-CMs reduced OCR, 
we considered if increased glycolysis (Figure 5E) contrib-
uted to these changes. Cardiomyocytes preferentially 
metabolize fatty acid oxidation for ATP production, but 
use glycolysis to supplement energetic demands, in par-
ticular, in response to stresses.39,40 Using tandem mass 
spectrometry to assess metabolomics, we found that, 
in comparison with WT, MYH7R403Q/+ iPSC-CMs had in-
creased levels of metabolomic by-products associated 
with active glycolysis (Figure 5F through 5K), as did LV 
tissues from Myh6R403Q/+ and Myh6R719W/+ in comparison 
with WT mice (Figure III in the online-only Data Supple-
ment). Consistent with the increased mitochondria con-
tent and OCR levels, tricarboxylic acid metabolites were 
significantly increased in MYH7R403Q/+ iPSC-CMs (Figure III 
in the online-only Data Supplement).
Together these experiments link destabilization of 
the IHM by pathogenic myosin variants with altered 
proportions of DRX and SRX conformations, hypercon-
tractility, poor relaxation, hypertrophic remodeling of 
cardiomyocytes, increased mitochondrial content, and 
energetic and metabolic stress. Because pharmacologi-
cal normalization of SRX/DRX ratios ameliorated down-
stream functional abnormalities, we conclude that the 
physiological regulation of myosins in DRX and SRX con-
formations is central to cardiac homeostasis, and that 
chronic dysregulation of myosin conformations is the 
fundamental pathophysiologic basis for HCM.
IHM Destabilization Predicts Adverse 
Clinical Outcomes
Because IHM destabilization defined a cellular mecha-
nism by which 3 pathogenic MYH7 variants cause HCM, 
and because restabilization of the IHM subverted these 
cellular phenotypes, we considered whether additional 
MYH7 amino acid substitution, specifically variants with 
unknown significance (VUS) also destabilized the IHM. 
Using these data, we assessed associations with clinical 
outcomes of the patients with HCM.
A clinical study of >4500 patients with HCM enrolled 
in the SHaRe showed that participants with pathogenic 
variants in sarcomere protein genes had the highest rates 
of heart failure and atrial fibrillation.14 However, many 
human MYH7 missense variants that are identified in pa-
tients with HCM cannot be definitively classified as patho-
genic or benign and are designated VUS. Among SHaRe 
participants, the rates of heart failure and atrial fibrillation 
among patients with sarcomere VUS was intermediate, 
below that observed in patients with pathogenic sarco-
mere variants (SARC+), but higher than in patients with-
out sarcomere variants (SARC–). We hypothesized that 
the intermediate risk associated with VUS resulted from 
poor annotation of variants and the combined outcomes 
of patients with variants that were actually pathogenic 
and patients with benign variants. To test this model, we 
reclassified MYH7 VUS, on the basis of whether the vari-
ant altered residues participating in the IHM (VUS–IHM+) 
or not (VUS–IHM–). We then asked if the lifetime burden 
of heart failure and atrial fibrillation differed between pa-
tients who had HCM with VUS–IHM+ and VUS–IHM– by 
comparing these outcomes in 2281 patients with HCM 
stratified by genotype: 537 with pathogenic variants, 55 
with VUS–IHM+, 78 with VUS–IHM–, and 1611 without 
sarcomere variants (Figure  6A and 6B and Figure IV in 
the online-only Data Supplement). Rates of heart failure 
and atrial fibrillation were significantly higher in patients 
in the VUS–IHM+ group than those in the VUS–IHM– and 
SARC– groups (Figure 6A through 6C).
We corroborated these observational studies by Mant-
ATP assays of human cardiac ventricular tissues from pa-
tients with HCM (See Table II in the online-only Data Sup-
plement for details) with pathogenic variants (MYH7R403Q/+ 
and MYH7R719W/+), VUS–IHM+ (MYH7R17C/+ and MY-
H7A226V/+), and VUS–IHM– (MYH7Y833H/+, MYH7E1039G/+, and 
MYH7R1606C/+). Both VUS–IHM+ and one VUS–IHM– (MY-
H7Y833H/+) reside within the S1 domain of myosin, as do 
both pathogenic variants (Figure 2A and 2C). Two other 
VUS–IHM– reside in the myosin light meromyosin domain 
(Figure 2A). Similar to pathogenic HCM variants, cardiac 
tissues with either VUS–IHM+ increased the proportion of 
myosins in DRX in comparison with SRX conformations 
(Figure 6D through 6G). By contrast, the proportion of 
myosins in DRX and SRX conformations in VUS–IHM– tis-
sues were comparable to the physiological levels found 
in the healthy human heart. Application of MYK-461 to 
human heart tissues from patients with VUS–IHM+ or 
with pathogenic variants MYH7R403Q/+ and MYH7R719W/+ 
normalized the SRX/DRX ratios (Figure 6F and 6G).
Figure 4 Continued. Assessment of oxygen consumption rate (OCR) was performed with the application of compounds to assess ATP production (Oligomycin), 
maximum (Max) respiration (FCCP, carbonyl cyanide-4 [trifluoromethoxy] phenylhydrazone) and halted respiration (antimycin A and rotenone) for WT or mutant 
MYH7403/+, MYH7606/+, MYH7719/+ iPSC-CMs. F, Basal OCR of naive WT MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs or after 24-hour MYK-461 0.3 μmol/L treat-
ment. G, Basal OCR of naive WT MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs or after 2-deoxy-d-glucose (2-DG) treatment. * denotes significance of P<0.05, 
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Figure 5. MYH7 variants that destabilize the interacting heads motif alter cellular metabolism.
A, Mass spectrometry assessment of total cell phosphocreatine (PCr) abundance in WT, and combined MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs. B, Mass 
spectrometry assessment of total cell adenosine triphosphate (ATP) abundance in WT, and combined MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs. C, Mass 
spectrometry assessment of total cell PCr/ATP in WT, and combined MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs. D, Mass spectrometry assessment of total cell 
NAD/NADH in WT, and combined MYH7403/+, MYH7606/+, and MYH7719/+ iPSC-CMs. E, Analyses of metabolic pathways involved in glycolysis. Glycolytic interme-
diates marked with red boxes were assessed by mass spectrometry. F through K, Glycolytic pathway intermediates detected in WT and MYH7403/+ iPSC-CMs. 
(See also Figure III in the online-only Data Supplement). All data were obtained from day 30 cultures of ≥2 independent differentiations, per genotype, and are 
displayed as mean±SEM. One-way ANOVA and 2-way ANOVA with post hoc Bonferroni correction for multiple comparisons were used for A and C and D, respec-
tively. t tests defined statistical significance in F through K. a.u. indicates arbitrary units; Fructose-1,6-P2, fructose 1,6-bisphosphate; iPSC-CMs, isogenic cardiomyo-
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The necessity for continual contractile performance by 
the heart mandates extraordinary sarcomere efficiency, 
matching power output with energy supplies, especially 
because cardiomyocytes have virtually no self-renewal 
and must continue to beat 2 billion times in the average 
lifetime. To accomplish this feat, the human heart is esti-
mated to consume 6 kg of ATP each day,41 a substantive 
energy requirement that is predominantly attributed to 
Figure 6. Myosin VUS that alter IHM residues are associated with higher rates of adverse clinical outcomes.
A, Kaplan-Meier curves show relative time points at which SHaRe subjects, grouped according to genotype, meet composite heart failure end points (first occur-
rence of cardiac transplantation, LV assist device implantation, LV ejection fraction <35%, or New York Heart Association class III/IV symptoms). Genotypes are 
denoted as pathogenic sarcomere variants (SARC+), no pathogenic sarcomere variants (SARC–), variant of unknown significance that alters an IHM residue (VUS–
IHM+), and variant of unknown significance that does not alter an IHM residue (VUS–IHM–). B, Kaplan-Meier curves demonstrate time to atrial fibrillation among 
SHaRe subjects with genotypes SARC+, SARC–, VUS–IHM+, and VUS–IHM–. (See also Figure IV in the online-only Data Supplement). C, Cox proportional hazard 
ratios comparing clinical SHaRe subjects with genotypes SARC+, SARC–, VUS–IHM+, and VUS–IHM– and adverse clinical outcomes of heart failure and atrial fibril-
lation. Significance was calculated using the log-rank test. D and E, Proportion of myosins in the SRX (D) and DRX conformations (E) in human ventricular tissues 
from healthy donor tissues (WT) or from HCM subjects with genotypes SARC+, VUS IHM+, (SARC–), and VUS IHM–. F and G, Proportion of myosin heads in SRX 
(F) and DRX (G) from healthy human ventricular tissues (WT) or HCM hearts with genotypes SARC+, VUS IHM+, (SARC–), and VUS IHM– region (VUS IHM +) 
before or after treatment with 0.3 μmol/L MYK461. All data are displayed with mean±SEM, and all significances are reported with a significance cutoff of P<0.05 
after using two-way ANOVA with Bonferroni corrections for multiple comparisons. DRX indicates disordered relaxed state conformation of myosin molecule; HCM, 
hypertrophic cardiomyopathy; HR, hazard ratio; IHM, interacting-heads motif; LV, left ventricular; LVEF, left ventricular ejection fraction; NS, not significant; SHaRe, 
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sarcomere contraction.42 By integrating structural, bio-
physical, biochemical, and clinical information, we pro-
vide evidence that dynamic conformations of myosin 
molecules are central to balancing muscle work and met-
abolic costs that impact sarcomere function, efficiency, 
and patient outcomes. We found that hibernating mam-
mals, with limited energy stores, increase the proportion 
of myosins in the SRX conformaton in comparison with 
active myosins as a physiological adaptation to reduce the 
energy demands, and contractility of myocardium during 
torpor. Reciprocally, human HCM mutations that reduced 
the proportion of  myosin in  the  SRX conformation  re-
sulted in increased contractility at the expense of higher 
energetic demands and impaired relaxation. Restoration 
of appropriate proportion of myosin in the SRX confor-
mation by an allosteric myosin modulator normalized bio-
physical and metabolic abnormalities, providing evidence 
for the primacy of myosin conformations in sarcomere 
efficiency and cellular homeostasis.
Our analyses of MYH7 VUS confirmed the impor-
tance of the IHM in enabling dynamic conformational 
changes in myosins. Only VUS that destabilized the 
IHM interactions had increased proportions of myosins 
in DRX, and patients with these VUS had high rates of 
heart failure and atrial fibrillation, comparable to those 
observed in patients with pathogenic HCM mutations. 
These data support the relevance of leveraging IHM 
structural models to improve molecular prediction of 
clinically actionable human variants.
The myosin phylogeny is highly evolutionarily con-
served, in particular, myosin II molecules that include 
ancient myosins, and cardiac myosins, as well.25 These 
ATP-fueled motor proteins are found in muscle and non-
muscle cells and function in cell division, migration, con-
traction and relaxation, endocytosis and exocytosis, and 
cell shape. Evolutionary conservation of protein motifs 
has implied functional importance of myosin domains in-
volved in binding actin, ATP hydrolysis, and interactions 
with other proteins. We suggest that this evolutionary 
conservation extends to IHM residues, based on analy-
ses of mouse LV (predominantly Myh6 protein) and hu-
man LV (predominantly MYH7 protein). The IHM motif 
enables myosin head-head and head-tail interactions 
that promote or limit actomyosin engagement and ATP 
hydrolysis. That these conformations that are conserved 
across species evolution strongly infers that efficient reg-
ulation of myosin activity and ATP consumption is critical.
We demonstrate the cellular effects of physiological 
dysregulation of myosin conformations. Hibernating 
ground squirrels had 10% more cardiac myosins in the 
SRX conformation than when squirrels were active. Be-
cause myosins in the SRX conformation consume 5-fold 
less ATP,11 this shift in myosin conformations is predicted 
to provide a 17.5% reduction in energy usage, a con-
siderable savings for fuel-starved hibernating animals. 
We observed a similar degree of conformational shift in 
myosin with HCM variants, albeit with increased propor-
tion of myosins in the DRX, not SRX conformation. Be-
cause pathogenic MYH7 variants are expressed lifelong, 
this shift would chronically increase energy usage and a 
substantial metabolic burden on cardiomyocytes. More-
over, because our experiments in unloaded hearts and 
cells that could underestimate these effects, we expect 
that physiological and pathological hemodynamic stress 
would also cause conformational shifts in myosins that 
further exacerbate energy depletion. Consistent with 
these observations, mutant iPSC-CMs had increased mi-
tochondrial content, and, despite this, adopted a stress-
induced transcriptional and metabolic profile, using gly-
colysis, and fatty acid oxidation, as well, to generate ATP.
Although our experiments were focused at the level of 
cardiomyocytes, these data may explain multiple in vivo 
phenotypes of HCM: hyperdynamic contraction, poor 
relaxation, hypertrophy, and increased energy consump-
tion. Although hypertrophic remodeling increases LV wall 
thickness and reduces cavity volumes, hyperdynamic 
contraction and poor relaxation predates these morpho-
logical changes.43 Consistent with these observations, the 
coincident increase in myosin DRX proportions and car-
diomyocyte systolic shortening observed here indicates 
that hypercontractility is a direct biophysical response to 
HCM mutations. Although we did not assess calcium sen-
sitivity iPSC-CMs, which have immature development of 
the calcium-handling apparatus, hyperdynamic contrac-
tion may reflect primary or secondary increases in calcium 
sensitivity, as has been observed in HCM mouse models30 
and human HCM tissues.44 Chronic hyperdynamic con-
traction might also contribute to hypertrophy, similar to 
the effects of conditioning exercises on muscle mass of 
highly trained athletes.45 Concurrent with the increased 
proportion of myosins in DRX, the reduced proportions 
of myosins in SRX conformations are likely to be an im-
portant cause for poor relaxation in HCM hearts that 
contributes to patients’ outcomes. Impaired ventricular 
relaxation and compliance impedes atrial emptying that, 
when chronic, leads to dilation of the thin-walled atrial 
chamber to promote atrial fibrillation, an arrhythmia that 
occurs in >20% of patients with HCM.46
Energetic abnormalities are also prominent in patients 
with HCM47 and precede morphological phenotypes of 
cardiac hypertrophy,48 indicating that these too are proxi-
mal consequences of mutations. The association of shift-
ing mutant myosins toward DRX with profound deficits in 
normal metabolic profiles in mutant iPSC-CMs22 provided 
a plausible explanation for these early energetic abnormali-
ties, although more comprehensive analyses are warrant-
ed. The heart depends on efficient ATP production from 
mitochondrial oxidative phosphorylation, which is estimat-
ed to supply 95% of the myocardial ATP requirements.49 
Although the heart can activate glycolysis to acutely meet 
increased energetic demands, a shift away from use of fatty 
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in ATP production, and this metabolic reprograming is a 
recognized mechanism for heart failure.50 As such, the in-
creased rates of heart failure in patients who have HCM 
with either pathogenic mutations or VUS that disrupt the 
IHM support our conclusion that myosin conformations 
are central regulators of cardiomyocyte metabolism. In 
addition, these data provide the opportunity to recognize 
patients at highest risk for heart failure, a substantial con-
tributor to premature death in HCM.14
In summary, demonstration that pathogenic MYH7 
variants destabilize the IHM not only alter the mechani-
cal properties of the sarcomere, but also incite profound 
changes in cardiomyocyte physiology, provides mechanis-
tic insights into the major clinical manifestations of HCM: 
hypertrophic remodeling, hypercontractility, poor relax-
ation, and excessive energy consumption. Because these 
cellular phenotypes are the likely underpinning of atrial 
fibrillation and heart failure, strategies to restore physi-
ological regulation of myosin conformations may limit 
these adverse clinical outcomes in patients with HCM.
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